Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipapkinogene sovacivec in High Grade CIN 2/3
NCT01022346Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2009
- Primary completion
- Sep 2013
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
A Phase 2 trial of tipapkinogene sovacivec in cervical intraepithelial neoplasia (CIN), sponsored by Roche. Started Aug 2009; status: completed.
02
Drugs
tipapkinogene sovacivec
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT01022346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01022346.